Mylan Inc. Expresses Support for National HIV Testing Day

PITTSBURGH, June 27, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), today expresses its support for National HIV Testing Day, an annual campaign to encourage people of all ages to be proactive and know their HIV status. According to the Centers for Disease Control and Prevention (CDC), more than 1.1 million people in the U.S. are living with HIV and 1 in 5 does not know they are infected. Getting tested is the first step in taking control of your health.

CEO Heather Bresch commented, “About half of all new HIV infections in the U.S. are attributed to the 20% of HIV-positive individuals who do not know they are infected. Knowing your status is a powerful step toward lowering the rate of HIV infections and ultimately eliminating the disease altogether.”

There are 50,000 new cases of HIV infection every year in the U.S., according to the CDC, and over half of these infections occur in people ages 12 to 34. Recent studies have shown that HIV-positive people who are on antiretroviral medications (ARVs) can expect to live a long and healthy life with no increased risk of mortality, and are 96% less likely to transmit the virus to others.

Bresch continued, “The U.S. Department of Health and Human Services guidelines state that all people living with HIV in the U.S. are eligible for life-saving ARVs regardless of their disease progression. Mylan is dedicated to helping those infected with HIV live life to its fullest potential by providing access to more affordable versions of these medications.”

Knowledge is power in the fight against HIV/AIDS. To find a testing site near you, visit hivtest.cdc.gov or text your zip code to KNOWIT (566948).

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what’s right, not what’s easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don’t take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.